Abstract
Shigella dysenteriae type 1 and Escherichia coli O157:H7 produce Shiga toxin (Stx) and Shiga toxin (Stx1), respectively and these two toxins are almost identical. E. coli O157:H7 is the major cause of diarrhea-associated hemolytic uremic syndrome. Stx and Stx1 are AB5 type of toxin with a molecular weight of 70 kDa, comprising an enzymaticalyactive A subunit (32 kDa) and five receptor-binding B subunits (7.7 kDa). In this study DNA fragment (289 bp, Gene Bank Accn No. EF685161) coding for B chain of Stx was amplified from S. dysenteriae type1 and cloned. Shiga toxin-binding subunit was expressed and purified in native conditions by affinity and gel permeation chromatography with the yield of 5.1 mg/L in shake flask culture. For the purpose of immunization, the polypeptide was polymerized with glutaraldehyde. Hyper immune serum produced in mice reacted with the purified polypeptide and intact Shiga toxin. The anti- StxB antiserum effectively neutralized the cytotoxicity of Shiga toxin towards HeLa cells.
Keywords: S. dysenteriae type1, Shiga toxin, Shiga like toxin, cytotoxicity, hemolytic uremic syndrome (HUS)
Protein & Peptide Letters
Title: Antibodies Against Recombinant Shiga Toxin Subunit B Neutralize Shiga Toxin Toxicity in HeLa Cells
Volume: 17 Issue: 6
Author(s): Pallavi Gupta, Manglesh Kumar Singh, Padma Singh, Mugdha Tiwari and Ram Kumar Dhaked
Affiliation:
Keywords: S. dysenteriae type1, Shiga toxin, Shiga like toxin, cytotoxicity, hemolytic uremic syndrome (HUS)
Abstract: Shigella dysenteriae type 1 and Escherichia coli O157:H7 produce Shiga toxin (Stx) and Shiga toxin (Stx1), respectively and these two toxins are almost identical. E. coli O157:H7 is the major cause of diarrhea-associated hemolytic uremic syndrome. Stx and Stx1 are AB5 type of toxin with a molecular weight of 70 kDa, comprising an enzymaticalyactive A subunit (32 kDa) and five receptor-binding B subunits (7.7 kDa). In this study DNA fragment (289 bp, Gene Bank Accn No. EF685161) coding for B chain of Stx was amplified from S. dysenteriae type1 and cloned. Shiga toxin-binding subunit was expressed and purified in native conditions by affinity and gel permeation chromatography with the yield of 5.1 mg/L in shake flask culture. For the purpose of immunization, the polypeptide was polymerized with glutaraldehyde. Hyper immune serum produced in mice reacted with the purified polypeptide and intact Shiga toxin. The anti- StxB antiserum effectively neutralized the cytotoxicity of Shiga toxin towards HeLa cells.
Export Options
About this article
Cite this article as:
Gupta Pallavi, Kumar Singh Manglesh, Singh Padma, Tiwari Mugdha and Kumar Dhaked Ram, Antibodies Against Recombinant Shiga Toxin Subunit B Neutralize Shiga Toxin Toxicity in HeLa Cells, Protein & Peptide Letters 2010; 17 (6) . https://dx.doi.org/10.2174/092986610791190291
DOI https://dx.doi.org/10.2174/092986610791190291 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Cardiogenic Shock in Acute Myocardial Infarction
Current Cardiology Reviews Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours
Anti-Cancer Agents in Medicinal Chemistry Computational Models of Neuronal Biophysics and the Characterization of Potential Neuropharmacological Targets
Current Medicinal Chemistry The Role of Coronary Collaterals in Chronic Total Occlusions
Current Cardiology Reviews Glycosphingolipid Structure and Function in Membranes
Current Organic Chemistry A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Current Alzheimer Research Reactive Metabolites in Early Drug Development: Predictive In vitro Tools
Current Medicinal Chemistry Disease Progression in Children with Vertically-Acquired HIV Infection in Sub-Saharan Africa: Reviewing the Need for HIV Treatment
Current HIV Research Recent Patents in Autophagy and Immune Response
Recent Patents on Inflammation & Allergy Drug Discovery Novel Therapies for Asthma - Advances and Problems
Current Pharmaceutical Design Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention
Current Molecular Medicine The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Heart Failure in North America
Current Cardiology Reviews Evaluation of Novel Biomarkers of Acute Kidney Injury: The Possibilities and Limitations
Current Medicinal Chemistry Serotonin 5-HT2A and 5-HT2C Receptors as Potential Targets for Modulation of Psychostimulant Use and Dependence
Current Topics in Medicinal Chemistry Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Current Alzheimer Research A Comparison of Emotional Decoding Abilities in Patients with Amnestic Mild Cognitive Impairment, Very Mild and Mild Alzheimer’s Disease
Current Alzheimer Research